ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

Core Insights - ProMIS Neurosciences Inc. has completed enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial for PMN310, targeting early Alzheimer's disease [1][4] - The trial is designed to provide clinically and biologically meaningful insights, with interim data expected in Q2 2026 and final results in Q4 2026 [1][3] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapeutics and vaccines for neurodegenerative diseases, including Alzheimer's disease, ALS, and Parkinson's disease [1][5] - The company utilizes its proprietary EpiSelect™ technology to identify Disease Specific Epitopes (DSEs) on misfolded proteins [5] Clinical Trial Details - The PRECISE-AD trial is a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics, and clinical effects of PMN310, which selectively targets toxic soluble amyloid-beta oligomers [2][8] - PMN310 has shown a favorable safety profile with no treatment-related serious adverse events reported and minimal patient discontinuations [3][4] Future Expectations - The upcoming blinded 6-month interim analysis in Q2 2026 will evaluate key biomarkers, followed by a final unblinded top-line analysis expected in Q4 2026 [3][8] - The trial's design aims to provide sufficient power to detect effects on biomarkers and clinical outcomes, with a focus on reducing amyloid-related imaging abnormalities (ARIA) [8]